Monte Rosa Therapeutics I... (GLUE)
| Bid | 4.19 |
| Market Cap | 279.87M |
| Revenue (ttm) | 75.62M |
| Net Income (ttm) | -72.7M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -4.64 |
| Forward PE | -2.78 |
| Analyst | Buy |
| Ask | 4.76 |
| Volume | 712,393 |
| Avg. Volume (20D) | 729,612 |
| Open | 4.26 |
| Previous Close | 4.41 |
| Day's Range | 4.26 - 4.63 |
| 52-Week Range | 3.21 - 12.40 |
| Beta | 1.53 |
About GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, ...
Analyst Forecast
According to 3 analyst ratings, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 251.65% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call TranscriptMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic ...
2 months ago · seekingalpha.com
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEENOne of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partn...